Cell Cure Neurosciences’s technologies and intellectual property portfolio are strengths it will use to address the need for cell-based therapies for neural degenerative disorders such as multiple sclerosis and Parkinson’s disease.

The National Multiple Sclerosis Society estimates that there are about 400,000 persons suffering from MS in the United States, and diagnosed cases are on the rise. Current therapies for multiple sclerosis are focused on slowing the progression of the disease as opposed to the development of a cure. To learn more about MS, please visit the Multiple Sclerosis Society.  According to the Parkinson’s Disease Foundation, Parkinson’s disease affects approximately one million people in the United States and more than four million people worldwide. The median age for the onset of all forms of Parkinson’s disease is 62 and the numbers of new cases is rising rapidly with the aging of the baby boomer population. There is currently no cure for the disease. To learn more about Parkinson’s please visit the National Institute of Neurological Disorders and Stroke.

Although in the early development stages of research, Cell Cure NeuroSciences’s scientists have created specific types of neural cells from hESC in the laboratory that may have benefit in targeting these devastating neural diseases.